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Abstract
Background: When a stop codon is located in the ribosomal A-site, the termination complex
promotes release of the polypeptide and dissociation of the 80S ribosome. In eukaryotes two
proteins eRF1 and eRF3 play a crucial function in the termination process. The essential GTPase
Sup35p, the eRF3 release factor of Saccharomyces cerevisiae is highly conserved. In particular, we
observed that all eRF3 homologs share a potential phosphorylation site at threonine 341,
suggesting a functional role for this residue. The goal of this study was to determine whether this
residue is actually phosphorylated in yeast and if it is involved in the termination activity of the
protein.
Results: We detected no phosphorylation of the Sup35 protein in vivo. However, we show that it
is phosphorylated by the cAMP-dependent protein kinase A on T341 in vitro. T341 was mutated to
either alanine or to aspartic acid to assess the role of this residue in the activity of the protein. Both
mutant proteins showed a large decrease of GTPase activity and a reduced interaction with eRF1/
Sup45p. This was correlated with an increase of translational readthrough in cells carrying the
mutant alleles. We also show that this residue is involved in functional interaction between the N-
and C-domains of the protein.
Conclusion: Our results point to a new critical residue involved in the translation termination
activity of Sup35 and in functional interaction between the N- and C-domains of the protein. They
also raise interesting questions about the relation between GTPase activity of Sup35 and its
essential function in yeast.
Background
The translation of genetic information into proteins is
essential for all biological systems. In eukaryotes, the
process is divided into at least three steps: initiation, elon-
gation and termination, and all three steps of translation
involve GTP-binding proteins and phosphorylations
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[1,2]. The structure of the GTP-binding proteins function-
ing at each step is well conserved from yeast to mammals,
and these proteins are fundamental to living cells [3]. In
the initiation and elongation steps, eIF2 and eEF1A,
which deliver, respectively, the methionyl-initiator tRNA
to the 40S ribosomal subunit and the aminoacyl-tRNAs to
the A-site of the ribosome, were identified as the GTP-
binding proteins [4] while in the termination step, it is
eRF3 [5,6].
Translation termination takes place on ribosomes when a
stop codon enters the ribosomal A site and signals
polypeptide chain release from the peptidyl-tRNA located
in the ribosomal P site. In eukaryotes, two polypeptide
chain release factors have been described: eRF1 recognizes
and decodes all three nonsense codons and eRF3 stimu-
lates peptidyl-tRNA hydrolysis in the ribosome in a GTP-
and eRF1-dependent manner [7-9]. Recent genetic and
biochemical data suggest that the GTPase activity is
required to couple the recognition of translation termina-
tion signals by eRF1 to efficient polypeptide chain release
[9,10]. Furthermore, reconstitution in vitro of the eukary-
otic translation initiation, elongation, and termination
processes made it possible to propose a model for the
mechanism of translation termination in eukaryotes.
Binding of eRF1, eRF3, and GTP to pretermination com-
plexes induces a major structural rearrangement that leads
to GTP hydrolysis for correct positioning of eRF1, fol-
lowed by rapid release of the nascent peptide [9]. Simi-
larly, in prokaryotes, RF3 is involved in recycling of RF1
and RF2 [11].
In the yeast Saccharomyces cerevisiae, eRF1 and eRF3 are
encoded by essential genes, SUP45 and SUP35, and often
designated as Sup45p and Sup35p, respectively. eRF1 and
eRF3 can interact both in vivo and in vitro [8,12-14]. The
eRF3 genes are conserved from yeast to mammals. In most
species examined, eRF3 consists of three domains (N, M
and C) whose functions have been defined for S. cerevisiae
eRF3. Both the N and M domains are dispensable for via-
bility and translation termination [15] in contrast to the
C-terminal region which carries the GTPase activity, inter-
acts with eRF1 and is indispensable [16]. All the mutants
isolated up to now, showed a correlation between GTPase
activity and viability.
The C-terminal domain of the eRF3 proteins is highly con-
served between species and shows significant homology
[16], as well as close structural similarities [17] to the
elongation factor eEF1A. In S. cerevisiae, and also in other
budding yeast species, the N and M domains are respon-
sible for the formation of the prion-like [PSI+] factor [18-
21]. In [PSI+] (but not in [psi-]) cells, eRF3 forms aggre-
gates which lead to defects in translation termination and
consequently to omnipotent nonsense suppression. The
N domains of higher eukaryotes have no obvious
sequence homology with the corresponding domains of
lower eukaryotes although, they have an unusual amino
acid composition as do the yeast proteins [22].
In this study, we identified a potential cAMP-dependent
protein kinase A (PKA) phosphorylation site in the C-ter-
minal region of the yeast Sup35 protein. We show that the
protein is phosphorylated in vitro by PKA on threonine
341 (T341), although no phosphorylation was detected in
the conditions tested in vivo. Alteration of this evolution-
ary conserved site modifies the in vivo and in vitro activity
of the protein in translation termination. Surprisingly our
results demonstrate that Sup35p mutants displaying very
low GTPase activity are able to support cell growth.
Results
Conservation of the phosphorylation site among 
organisms
The amino acid sequence R/K-R/K-N-S/T is the consensus
PKA recognition site, and either S or T is the phosphoryla-
tion site. A putative PKA phosphorylation site containing
threonine 341 (T341) is present in the S. cerevisiae eRF3
(Sup35p) sequence and is conserved among others yeasts
and fungi. In drosophila, human and mouse the site is
degenerated, but T341 still belongs to a phosphorylation
site, recognized by the CK2 protein kinase (Fig. 1). In a
sequence-based approach, the evolutionary conservation
of all PKA consensus sites in the S. cerevisiae proteome was
systematically assessed within a group of related yeasts
[23]. The study demonstrated that the likelihood of phos-
phorylation correlated well with the degree of conserva-
tion of the PKA consensus sites. The evolutionary
preservation of the eRF3 phosphorylation site thus sug-
gests that this site probably plays an important role in vivo.
To test the functionality of the PKA phosphorylation site
Alignment of eRF3 protein sequences Figure 1
Alignment of eRF3 protein sequences. The 60 amino 
acids surrounding the T341 residue are shown, with the PKA 
phosphorylation consensus site shaded. Nc, Neurospora 
crassa; Pa, Podospora anserina; Sp, Schizosaccharomyces pombe; 
Sc, Saccharomyces cerevisiae; Kl, Kluyveromyces lactis; Dh, 
Debarromyces hansenii; Ca, Candida albicans; Pp, Pichia pinus; 
Yl, Yarrowia lipolitica; Hs, Homo sapiens; Mm, Mus musculus; 
Dm, Drosophila melanogaster; Ce, Caenorhabditis elegans; At, 
Arabidopsis thaliana.
eRF3_Pp     SWIMDTNKEERNDGKTIEVGKSYFETDKRRYTILDAPGHKLYISEMIGGASQADVGVLVI 406 
eRF3_Ca     SWVMDTNKEERNDGKTIEVGKAYFETDKRRYTILDAPGHKMYVSEMIGGASQADVGILVI 402 
eRF3_Sc     SWVMDTNKEERNDGKTIEVGKAYFETEKRRYTILDAPGHKMYVSEMIGGASQADVGVLVI 347 
eRF3_Dh     SWVMDTNKEERSDGKTIEVGKAYFETEKRRYTILDAPGHKMYVSEMIGGASQADVGILVI 369 
eRF3_Kl     SWVMDTNKEERNDGKTIEVGRAYFETEKRRYTILDAPGHKMYVSEMIGGASQADIGILVI 383 
eRF3_Yl     SWVMDINKEERAEGKTVEVGRSYFETEKRRYTLLDAPGHKMYVPSMIGGAAQADAGILVI 387 
eRF3_Nc     SWALDLTNEERAKGKTVEVGRGFFETDKRKYSILDAPGHKTYVPNMIGGASQADVGILVI 398 
eRF3_Pa     SWALDLTNEERSKGKTVEVGRGFFETDKRRYSILDAPGHKTYVPNMIGGASQADVGILVI 427 
eRF3_Sp     SWALDSTSEEREKGKTVEVGRAYFETEHRRFSLLDAPGHKGYVTNMINGASQADIGVLVI 428 
GSPT1_Hs    SWALDTNQEERDKGKTVEVGRAYFETEKKHFTILDAPGHKSFVPNMIGGASQADLAVLVI 317 
GSPT1_Mm    SWALDTNQEERDKGKTVEVGRAYFETEKKHFTILDAPGHKSFVPNMIGGASQADLAVLVI 271 
eRF3_Dm     SWALDTNQEERDKGKTVEVGRAFFETDRKHFTILDAPGHKSFVPNMIGGAAQADLAVLVI 304 
eRF3_Ce     SWCMDTNDEEREKGKTVEVGRAYFETEKRHFTILDAPGHKSFVPNMIVGANQADLAVLVI 218 
eRF3_At     AYIMDTNEEERLKGKTVEVGRAHFETESTRFTILDAPGHKSYVPNMISGASQADIGVLVI 210 
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of Sup35p, we generated threonine to alanine (A) or
aspartate (D) mutants. Alanine ca0nnot be phosphor-
ylated, whereas aspartate mimics the presence of phos-
phate groups.
Sup35p is phosphorylated in vitro by PKA
His-Tag fusion polypeptides, with either the entire full-
length wild-type Sup35p or the A and D mutants, were
generated in E. coli and purified by Ni2+-nitrilotriacetic
acid affinity chromatography. The purified proteins were
incubated with the PKA catalytic subunit and [γ-32P]ATP.
Incubation of wild-type Sup35p resulted in the appear-
ance of a 32P-labeled species of 78 kDa (the expected
apparent molecular mass of Sup35His) (Fig. 2a). Phos-
phorylation was completely inhibited by PKI, a specific
inhibitor of PKA. Incubation of either mutant A or D with
PKA and [γ-32P]ATP resulted in a reduced phosphoryla-
tion. (Fig. 2b). Therefore, the T341 residue of Sup35p is
phosphorylated in vitro by PKA, and the consensus phos-
phorylation site of Sup35p is not the only one to be phos-
phorylated by PKA in vitro. This is not surprising as kinases
are known to also have non specific activity in in vitro con-
ditions.
To verify the phosphorylation state of the T341 residue, in
vitro phosphorylated wild-type, A and D proteins were
submitted to western blot analysis using an antibody spe-
cific of substrates phosphorylated by PKA. As expected,
only the phosphorylated wild-type protein was detected,
the phosphorylated A and D proteins were not, and none
of the non-phosphorylated proteins was revealed by the
antibody (Fig. 2c).
The expression of full-length Sup35p was relatively poor
in E. coli cells, while a much greater amount of protein
could be recovered from constructs expressing the C-ter-
minal domain alone. Furthermore, the purified full-
length proteins were unstable and precipitated rapidly
upon storage, probably due to the presence of the aggre-
gating N-terminal domain. Consequently, the same exper-
iments were performed with the C-terminal part of the
wild-type, A or D mutant proteins purified as His-Tag
fusion polypeptides from E. coli. We wondered if the
Sup35pcter [C-terminus] alone could be phosphorylated
by PKA in vitro. The results show that the truncated pro-
teins behaved as did the corresponding full-length pro-
teins. The C-terminal part of Sup35p was phosphorylated
by PKA in vitro, and the A and D mutants were also phos-
phorylated but to a much lower extent (Fig. 2d).
To search for a difference in electrophoretic mobility
between the in vitro phosphorylated and non-phosphor-
ylated protein forms, we performed SDS-polyacrylamide
gels in various conditions (see Materials and Methods),
but no change in the electrophoretic migration was seen
between the protein forms (not illustrated).
The in vitro phosphorylated residue is threonine 341
To check which residue was phosphorylated by PKA in
vitro, the phosphorylated full-length His-Tag fusion
Sup35p was subjected to mass spectrometry analysis. The
MALDI mass spectrum of the unfractioned tryptic digest
S. cerevisiae Sup35p is phosphorylated by PKA in vitro Figure 2
S. cerevisiae Sup35p is phosphorylated by PKA in vitro. 
Proteins were incubated with the PKA catalytic subunit and 
[γ-32P]ATP, submitted to SDS-PAGE, and visualized by auto-
radiography. (a) Phosphorylation of wild-type Sup35p in the 
presence of PKA or PKI. (b) Phosphorylation of A and D 
mutant proteins by PKA. (c) Recognition of the different pro-
teins by a specific PKA-phosphorylated substrate antibody. 
Wild-type, A or D mutant proteins were phosphorylated or 
not by PKA before western blotting and detection using a 
secondary antibody linked to the alkaline phosphatase. (d) 
Phosphorylation of C-terminal proteins by PKA.
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allowed us to obtain 70% sequence coverage (Fig. 3a). A
peptide whose mass did not correspond to the mass of
any predicted tryptic peptide was detected, but it was
about 80 Da above the theoretical mass of the peptide
[339–349]. The possible presence of one phosphate group
was fully relevant, as long as the sequence of this tryptic
fragment is RYTILDAPGHK, and contains 2 potential
phosphorylation sites (Y340 and T341). This was con-
firmed by performing an on-target dephosphorylation
experiment (Fig. 3a). As the signal of the alkaline phos-
phatase-treated sample was diminished by 80 Da com-
pared to the untreated peptide, [339–349] was indeed a
mono-phosphorylated species.
To further investigate the phosphorylation site of the pep-
tide [339–349], we purified the tryptic digest by reversed
phase HPLC separation. Each fraction collected was ana-
lysed by MALDI mass spectrometry prior to and after on-
target dephosphorylation, and [339–349] was recovered
in the presence of two other minor peptides (data not
shown). Peptide [339–349] of the HPLC fraction was
sequenced by PSD-MALDI TOF mass spectrometry. The
PSD spectrum of the derivatised peptide [339–349] (m/z
1528.6565) is shown Fig. 3b. The β-elimination occurring
(H3PO4 loss) suggested phosphorylation on the T341 res-
idue rather than on Y340, because such β-elimination is
observed for phosphorylated serine or threonine, but not
for tyrosine. This was confirmed by the presence of a mass
difference between two adjacent peaks corresponding to a
dehydroamino-2-butyric acid product (i.e. 83 Da).
Search for a pool of phosphorylated Sup35p in vivo
To determine whether Sup35p is phosphorylated in yeast
cells, we labelled with [32P]orthophosphate a culture of
the SUP35-deleted strain that contains a plasmid-encoded
SUP35 wild-type gene fused to a C-terminal HA-Tag, and
immunoprecipitated Sup35p with an HA-specific anti-
body. Western blot analyses of the immunoprecipitated
proteins and the immunoprecipitation supernatants
showed that approximately one third of the Sup35 pro-
teins was immunoprecipitated. The same experiments
were performed using a strain deleted of PKA, and also in
a SUP35-deleted strain expressing a plasmid coding for
the A mutant protein fused to the HA-Tag and unable to
be phosphorylated on T341. Labelling and immunopre-
cipitation were carried out on exponentially growing cells,
as well as on stationary phase cells. In spite of numerous
attempts, we did not observe a radioactive pool of Sup35p
(data not shown). Since the FS1 strain carries a [PSI+]
determinant, it seemed possible that the aggregation of
Sup35p could alter protein phosphorylation, or decrease
immunoprecipitation efficiency and as a result could
reduce the immunoprecipitated sub-fraction of phospho-
rylated Sup35p. To test this possibility, similar experi-
ments were performed in a SUP35-deleted strain carrying
only the C-terminal domain of Sup35p, fused to a C-ter-
minal HA-Tag and again, no radioactive pool of Sup35p
was detected (data not shown).
Mutation T341D compromises cell viability, T341A does 
not
Complementation assays of a SUP35 gene deletion were
performed with the mutated alleles. A strain deleted for
the endogenous SUP35 gene and saved by an URA3 plas-
mid-encoded wild-type SUP35 gene was transformed with
a HIS3 vector carrying either the wild-type SUP35 gene, or
one of the mutants, or an empty vector. Plasmid shuffling
[24] was then carried out by plating the transformants
onto medium supplemented with 5-fluoroorotic acid, an
uracil analog that allows the formation of colonies only
from cells that have lost the wild-type SUP35  plasmid
with the URA3 marker. The ability to form colonies indi-
cates that the Sup35p mutant alone can support viability,
while the absence of colonies indicates that the mutant
form of Sup35p is unable to support cell viability. The
wild-type and the A mutant were able to grow but not the
D mutant, suggesting that the T341 residue is subjected to
functional constraints and that the introduction of a neg-
ative charge in this position alters cell viability. The A
mutant behaved like the wild-type strain and did not
show thermosensitivity at 37°C (data not shown). A
glutamate mutant (T341E) was also constructed to mimic
the presence of phosphate groups, and presented the same
phenotypes as the D mutant. The essential function of
Sup35p is located in the C-terminal domain, thus C-ter-
minal-T341A and C-terminal-T341D mutants were also
constructed and used in such a complementation assay as
above. Surprisingly, both mutants were able to comple-
ment the loss of wild-type Sup35p (Fig. 4), indicating that
the N-terminal part of Sup35p might be implicated in the
lethality observed in presence of the full-length Sup35p D
mutant.
T341D Sup35p is not degraded in vivo
To check if the lethality of the D mutant was due to the
degradation of the protein, western blot analyses were car-
ried out to monitor the steady-state levels of the mutant
forms of Sup35p. Protein extracts were obtained from
SUP35-deleted strains carrying either one of the mutated
full-length alleles on a centromeric HIS3 plasmid (saved
by the plasmid-encoded C-terminal part of the SUP35
wild-type gene). To permit valid comparisons, the
amounts of total protein extract loaded per well were the
same. The results indicate that each mutant form of
Sup35p was present at a steady-state level similar to that
of the wild-type Sup35p (Fig. 5). Thus the incapacity of
the full-length D mutant to grow does not result from
Sup35p degradation.BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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Mass spectrometry analysis of phosphorylated Sup35p Figure 3
Mass spectrometry analysis of phosphorylated Sup35p. (a) On-target dephosphorylation. Detail of the total tryptic 
digest mass spectra prior and after alkaline phosphatase treatment. The 80 Da shift is the typical signature for a mono-phos-
phorylated peptide. (b) PSD-MALDI spectrum of the CAF-derivatised peptide [339–349] (HPLC fraction n°22). The neutral 
loss of H3PO4 (98 Da) converts pThr into dehydroamino-2-butyric acid produced by β-elimination and the "CAF" gap corre-
sponds to the initial loss of 136 Da from the sulphonic acid group.
 
(a) 
 
 
 
 
 
(b) 
 
1267.0 1285.2 1303.4 1321.6 1339.8 1358.0 
Mass (m/z) 
1.3E+4 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
%
 
I
n
t
e
n
s
i
t
y
 
1267.0 1285.2 1303.4 1321.6 1339.8 1358.0 
Mass (m/z) 
4089.6 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
%
 
I
n
t
e
n
s
i
t
y
 
1270.7036
1270.6674 
1350.6166 
[339-349] 
[339-349] + 1P 
+ Alkaline Phosphatase
-80 Da shift
P
e
a
k
 
d
i
s
a
p
p
e
a
r
a
n
c
e
 
72.0 376.2  680.4 984.6 1288.8 1593.0  Mass (m/z) 
4.4E+4 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
%
 
I
n
t
e
n
s
i
t
y
 
1431.1 
1528.7 
1401.
H3PO4  CAF  R  Y 
pT- H3PO4 
I/L  I/L  D  A  PG  H 
Derivatised 
peptide 
y11
y1 y
y8
y
y6 
y5 
y y
M = 83 Da BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
Page 6 of 14
(page number not for citation purposes)
The Sup35pcter T341A and T341D mutations decrease the 
efficiency of translation termination in vivo
Mutations in the gene encoding eRF3 have frequently
been reported to exhibit an omnipotent suppressor phe-
notype, where readthrough is thought to increase at all
stop codons [16,25]. We examined how mutation of T341
affected the efficiency of translation termination at each of
the three stop codons by using a dual reporter system [26].
The dual reporter plasmids contain an upstream lacZ gene
and a downstream firefly luciferase gene separated by dif-
ferent in-frame stop codons in the Tobacco Mosaic Virus
readthrough context. These constructs made it possible to
monitor the translation readthrough of different termina-
tion signals in different genetic contexts by measuring fire-
fly luciferase activity, while the β-galactosidase activity
served as an internal normalization control.
The  SUP35-deleted strain saved by either a plasmid-
encoded C-terminal wild-type, C-terminal A mutant or C-
terminal D mutant gene was transformed with the dual
reporter constructs, readthrough activities were measured
and statistical analyses using the Mann-Whitney non par-
ametric test were performed [27]. Yeast strains expressing
the C-terminal A or D Sup35p as the sole source of Sup35
protein exhibited a significantly increased readthrough
level compared to cells expressing wild-type Sup35p (Fig.
6). The readthrough efficiency of the A mutant was 1.4 to
1.8 fold higher than the wild-type (P value TAG =
0.00333, TGA = 0.00177, TAA = 0.00177). The D mutant
showed a stronger increase in readthrough with increase
factors ranging from 3.4 for the TAG codon (P value =
In vivo translation termination efficiency of T341A  Sup35pcter and T341D Sup35pcter Figure 6
In vivo translation termination efficiency of T341A 
Sup35pcter and T341D Sup35pcter. Percent 
readthrough of the three different stop codons (TAG, TGA 
and TAA) carried on a dual reporter system was estimated in 
strains expressing the C-terminal Sup35p either wild-type, A 
mutant or D mutant, as sole source of Sup35 protein.
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Full-length T341D compromise viability whereas the 
C-terminal T341D does not. Both full-length and C-
terminal T341A are compatible with viability. The 
strain deleted for endogenous SUP35 and rescued by an 
URA3 plasmid containing the wild-type SUP35 gene was 
transformed with either pRS313-SUP35, pRS313-SUP35A, 
pRS313-SUP35D (HIS3 plasmids) or with pFL36-SUP35cter, 
pFL36-SUP35Acter and pFL36-SUP35Dcter (LEU2 plasmids). 
Transformants were streaked onto 5FOA to eliminate the 
URA3 plasmid containing the wild-type copy of SUP35.
 
The T341D Sup35 protein is not degraded in vivo Figure 5
The T341D Sup35 protein is not degraded in vivo. For 
each strain, the same amount of total proteins was separated 
by SDS-PAGE and western blot analysis shows the amount of 
Sup35p in each sample (wild-type (WT), A or D mutants). 
Detection was made using a primary antibody specific of the 
M domain of Sup35p, and a secondary antibody fused to the 
horseradish peroxydase.
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0.00214) and 3.6 for the TAA codon (P value = 0.00044),
to 4.2 (P value = 0.00044) for the TGA codon compared
to the wild-type C-terminal Sup35p.
GTPase activity of the A and D mutants
The Sup45p- and ribosome-dependent GTPase activity of
the A and D mutant Sup35pcter was checked in vitro by
accumulation of [32P]Pi using the modified charcoal pre-
cipitation assay as described [7]. The D mutant was prac-
tically inactive in the GTPase assay whereas the A mutant
exhibited residual GTPase activity (6% compared to the
wild-type Sup35pcter) (Table 1).
Interaction of A and D Sup35 proteins with Sup45p (eRF1)
Translation termination is triggered by a complex consist-
ing of Sup45p and Sup35p [9]. We analyzed the capacity
of the A and D mutant proteins to interact with the
Sup45p partner by a two-hydrid approach. Interactions
were visualized by growth on a medium lacking histidine
with 10 mM 3-aminotriazol added. The two mutant
Sup35 proteins could still interact with Sup45p, but with
various efficiencies. The results indicated strong interac-
tion between the wild-type proteins, decreased interaction
between Sup45p and the Sup35p A mutant, and the weak-
est between Sup45p and the Sup35p D mutant (Fig. 7).
The frequency of diploid cells interacting with each others
was estimated for these three diploids. Three independent
cultures were prepared in minimal medium lacking urac-
ile and leucine for each diploid, and plated onto either a
minimal medium lacking histidine, uracile and leucine to
count the cells presenting a Sup35p and Sup45p interac-
tion, or a minimal medium lacking uracile and leucine to
count diploid cells. The results indicated an interaction in
64% of the cells between the wild-type proteins, in 22%
of the cells between the Sup35p A mutant and Sup45p,
and in 15% of the cells between the Sup35p D mutant and
Sup45p.
A similar picture of various interaction efficiencies of the
A and D mutant Sup35pcter with Sup45p was also
observed in another in vitro assay. It was shown that
Sup35p can stimulate the RF activity of Sup45p in an in
vitro  system at low stop codon concentration while
Sup45p alone at the same concentration of stop codon is
inactive [8,28]. The stimulation of Sup45p activity in the
presence of Sup35p might be caused by mutual interac-
tion of these proteins. The RF stimulating activity of
Sup35pcter towards Sup45p was measured as described
[8]. The stimulating RF activities of the A and D mutant
Sup35pcter towards Sup45p were 60 and 35%, respec-
tively compared to the wild-type Sup35pcter activity (not
shown).
Discussion
The C-terminal domain of Sup35p, implicated in transla-
tion termination, contains a consensus site for phosphor-
ylation by PKA. Alignment of eRF3 sequences showed that
this site is highly conserved. Kallmeyer et al. [29] already
addressed the absence of phosphorylation of Sup35p in
vivo, however Le Roy et al. [30] demonstrated differential
phosphorylation states of the human eRF3, which is
highly homologous to the yeast Sup35p. In addition, the
serine/threonine protein kinase Sch9, whose activity func-
tionally overlaps those of the PKA and TOR kinases, was
recently identified in a proteome-wide screen for protein-
protein interactions as forming a complex with, and pre-
sumably, phosphorylating Sup35p [31].
Phosphorylation being sometimes very labile, the modi-
fied isoforms might be difficult to detect. This led us to
run the experiment in conditions different from
Kallmeyer et al. We demonstrated that threonine 341 of
the consensus site was indeed phosphorylated in vitro by
PKA. However, in the in vivo conditions tested, no pool of
phosphorylated Sup35p was observed. Since Budovskaya
et al. [23] demonstrated that the presence of a highly con-
served PKA consensus site was a very strong predictor of
physiological PKA phosphorylation, we think it cannot be
excluded that phosphorylation could occur, but in partic-
ular conditions we did not explore yet. However, the sim-
plest interpretation is that Sup35 protein is actually not
phosphorylated in vivo. Indeed, in vitro phosphorylation
assays frequently identify non-physiological substrates for
various kinases.
Although no phosphorylation was detected in position
341, mutant forms of Sup35p, mimicking either a non-
phosphorylated (A mutant), or a constitutively phospho-
rylated (D mutant) protein were constructed, anticipating
that if phosphorylation actually occurs in particular phys-
Table 1: In vitro Sup45p- and ribosome-dependent GTPase activity of A and D mutant Sup35pcter.
Components of the incubation mixture 32P[Pi] released (pmol) Activity in % compared to the WT
Sup45p 0 -
Sup35pcter wild-type 0 -
Sup35pcter wild-type + Sup45p + ribosomes 2.2 100%
A mutant Sup35pcter + Sup45p + ribosomes 0.14 6%
D mutant Sup35pcter + Sup45p + ribosomes 0.02 1%BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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iological conditions, the residue involved would have an
important role in the function of the protein. These muta-
tions were incorporated either in the full-length protein or
in the essential C-terminal domain. An almost two fold
increase in the level of readthrough was observed with the
C-terminal form of the T341A mutant and a four fold
increase was observed with the C-terminal form of the
T341D mutant, compared to the wild-type. Consistent
with these results, both mutant forms showed decreased
interaction with Sup45p, indicating that the termination
complex is less actively formed. The highest readthrough
levels obtained in the A and D mutants were observed
with the TGA stop codon. This observation is consistent
with the hypothesis of Salas-Marco and Bedwell [10] that
Sup35p may help Sup45p discriminate between UGG and
certain stop codons.
When we checked for phenotypes, we found that strains
expressing the C-terminal form of either mutant are via-
ble, while the T341D mutation in the full-length protein
context was not able to support viability. Thus functional
interaction between the N- and C-terminal parts of
Sup35p is responsible for the lethality of the full-length D
mutant. The presence of the N-terminal part of Sup35p
was previously shown to decrease translation termination
efficiency in a [psi-] background [32]. Similarly, in a
recent work Volkov et al [33] found that the N terminus
acts as a negative factor, increasing nonsense suppression
efficiency in sup35 mutants containing amino acid substi-
tutions in the C-terminal domain. Therefore, one reason
for the lethal effect of the T341D mutation in the full-
length protein could be a too important rate of nonsense
readthrough, which could be incompatible with cell via-
bility. Strikingly, a Y340H substitution (the residue pre-
ceeding T341) directed higher stop codon readthrough
efficiencies in a full-length compared to a C-terminal con-
text, while not affecting the PKA consensus site. This is
consistent with the results reported here for the T341D
mutant. In the later case the consequence is even more
drastic since the presence of both domains leads to
lethality. Volkov et al. [33] concluded that the N-terminal
extension of Sup35p might decrease the GTPase activity in
strains that contain amino acid substitutions in the C-ter-
minal domain. In our case, the GTPase activity of the C-
terminal D mutant is already extremely low, but if it is suf-
ficient for cell growth, adding the N-terminal domain
could reduce it to a non viable level.
The T341 residue is located in the GTPase fold of Sup35p,
between the switch I and G2 switch II regions. The A and
D mutations most likely affect the Sup45p and ribosome-
dependent GTPase function of the resulting proteins,
since both of them display reduced GTPase activity in
vitro. The A mutation exhibits a strong reduction of
GTPase activity, and to date, the GTPase activity of
Sup35p was always shown to be essential for cell viability
[10]. In the C-terminal D mutant, the GTPase activity is
100 times lower than in the wild-type but it is still com-
patible with growth. Cell viability of both the full-length
and the C-terminal A mutant could be explained by the
residual GTPase activity (about 15 times less compared to
the wild-type Sup35p), since the concentration of Sup35p
in yeast is 6 times higher than the concentration of
Sup45p (1.31 104 protein molecules per cell for Sup45p
and 7.89 104 for Sup35p [34]). These results lead to two
interesting conclusions: 1) even with a 100 times lower
GTPase activity, this C-terminal D mutant is still active in
termination and supports viability; 2) there must be a
negative feedback link between this mutation in the C-ter-
minal domain and the N-M domains of Sup35p.
Salas-Marco and Bedwell [10] examined how mutations
in the GTPase domain of Sup35p influence translation
termination, and suggested that the GTPase activity of
Sup35p is required to couple recognition of translation
termination signals by Sup45p to efficient polypeptide
Interaction between Sup45p and wild-type, A or D mutant  Sup35 proteins in a two-hybrid system Figure 7
Interaction between Sup45p and wild-type, A or D 
mutant Sup35 proteins in a two-hybrid system. The 
entire SUP35 gene was fused to the binding domain of Gal4 
(Gal4-BD), and the SUP45 gene to the activating domain of 
Gal4 (Gal4-AD). Serial dilutions of diploids were spotted on 
YPD rich medium and on a medium lacking leucine, uracile 
and histidine with 10 mM 3-aminotriazol to reveal interac-
tions.
 BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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chain release. One of the mutants these authors described
(H348L), which is unable to support viability and has the
largest reduction in GTPase activity, could correspond to
our D mutant, but none of the other mutants was compa-
rable to the A mutant, with a growth similar to the wild-
type and a low GTPase activity, nor to the C-terminal D
mutant with its extremely low GTPase activity. Recent
findings shed light on the role of Sup35p in translation
termination [9]: based on in vitro evidences a model is
proposed where the GTPase activity is needed for the cor-
rect positioning of the Sup45p GGQ in the PTC. This
might lead to the release of Sup35p-GDP from the ribos-
ome or modify the interaction between Sup35p-GDP and
Sup45p. Sup45p would then trigger hydrolysis of the pep-
tidyl-tRNA. Our in vitro results are consistent with this
possibility since the stimulating RF activities of the A and
D mutant Sup35pcter towards Sup45p were clearly dimin-
ished.
Differences in protein activities between the mutants stud-
ied here most likely depend on the structure of Sup35p.
Only a small effect is observed on the interaction of the
mutated proteins with its Sup45p partner, but it is not an
"all or nothing" response, and is probably due to a change
in protein conformation. According to the crystal struc-
ture available for eRF3 of Schizosaccharomyces pombe [17],
the S319 residue, corresponding to S. cerevisiae T341, is
not directly involved in GTP binding but localizes at the
surface of the protein. Due to their high flexibility, large
portions of the switch I and II regions of the GTPase
domain were not defined by electron density and hence
are absent from the crystal structure (AA 280–307 and
325–331 are missing). It is therefore difficult to precisely
predict the impact of the mutations studied on the protein
structure. This region was speculated to become ordered
when the Sup45p/Sup35p-GTP complex associates with
the ribosome, thereby stimulating the GTPase activity of
Sup35p in the presence of Mg2+. In G proteins, it is well
documented that these switch regions adopt different
conformations depending on the nucleotide bound (GDP
or GTP) and on the coordinate Mg2+, which is an essential
cofactor for GTP hydrolysis [35]. The D mutation might
influence both regions, resulting in a dramatic conforma-
tional change and loss of GTP hydrolysis activity.
It has also been suggested that Sup35p might be impli-
cated in other pathways different than translation proc-
esses [32,36,37]. Recent data focused on the relation
between Sup35p and the cytoskeleton since it interacts
through its N-terminal domain with various proteins of
the actin cortical cytoskeleton. The T341D mutation
might thus lead to an altered protein unable to perform
these other functions. Since the interaction between
Sup35p and the cytoskeleton is not known to involve its
GTPase activity, it might be this pathway that is involved
in the essentiality of Sup35p. This would explain why the
D mutant, almost completely devoid of GTPase activity
and highly deficient in termination, is nevertheless viable.
Conclusion
In the present study, we characterized T341 as a new criti-
cal residue for peptide release factor Sup35p activity. We
demonstrate that this residue is involved in the activity of
Sup35p in translation termination and functionally inter-
acts with the N-terminal part of the molecule. That an
extremely low GTPase activity of Sup35p is compatible
with normal growth raises interesting questions about the
absolute requirement of this release factor for cell viabil-
ity. Indeed the indispensability of the protein was so far
related to its GTPase activity, and our work demonstrates
either that extremely low GTPase activity is sufficient for
cell growth, or that the protein is implicated in one or sev-
eral other essential pathways not requiring the GTPase
activity.
Methods
Strains, growth conditions and methods
The S. cerevisiae strains used here were FS1 (MAT α ade2-
592 (frameshift) lys2Δ201 leu2-3, 112 his3Δ-200 ura3-52)
which is derived from Y349 [38], and pJ69-4A for the two-
hybrid analysis (MAT a and α trp1-901 leu2-3, 112 ura3-52
his3Δ-200 gal4Δ gal80Δ GAL2-ADE2 LYS2::GAL1-HIS3
met2::GAL7-lacZ) (described in [39]). Standard rich
(YPD) or synthetic (SC) culture medium was prepared as
described [40]. The E. coli strain DH5α (supE44 Δlac U169
(Φ80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1)
was used for cloning experiments, and was cultivated in
LB medium [41]. Appropriate amounts of antibiotics,
amino acids and bases were added when necessary. Yeast
transformation was performed by the lithium acetate
method as described previously [42]. E. coli cells were
transformed as indicated [43]. For plasmid shuffling [44],
a selective medium containing 0,25% 5-fluoroorotic acid
(5-FOA, Fermentas) was used.
Gene disruption
The FS1 sup35Δ strain was generated by a one-step gene
replacement method. The SUP35 gene was disrupted by
the removal of the entire open reading frame and the
insertion of the ADE2 gene. Y349 genomic DNA was used
as template to generate the PCR fragment carrying the
ADE2  gene plus the promoter with the sense (5'-
TTCTTCATCGACTTGCTCGGAATAACATCTATATCT-
GCCCACTAGCAACAAACACC AACATAACACTGACATC)
and reverse (5'-CTTTATGATCGGTATTATTGTGTTT-
GCATTTACTTATGTTTGCAAGAAATGGACAC CTG-
TAAGCGTTGATTTC) primers, which contain extensions
corresponding to the flanking upstream and downstream
sequences of the SUP35 open reading frame, respectively.
The upstream (sense 5'-CGAGAAGATATCCATCATAT-BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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TACC and reverse 5'-TGTTGCTAGTGGGCAGATATAG
primers) and downstream (sense 5'-ATTTCTTGCAAA-
CATAAGTAAATG and reverse 5'-GCTTCTGAAGATAGAT-
GAGCGG primers) regions of the SUP35  gene were
amplified by PCR from FS1 genomic DNA. The three PCR
fragments were then joined by running a PCR reaction
with each of them in equimolar amounts, resulting in the
final disruption fragment. The yeast FS1 strain was trans-
formed with the disruption fragment and the centromeric
URA3 plasmid pRS316-SUP35. Ura+ Ade+ transformants
(white colonies) were tested for the ability to evict the
URA3 plasmid on 5-FOA plates. Clones which were una-
ble to grow on 5-FOA medium had integrated the ADE2
gene on the chromosome, and not on the pRS316-SUP35
plasmid. The correct genomic integration event was then
verified by PCR on the genomic DNA.
Plasmids
Centromere- and 2μ DNA-based plasmids were used to
express wild-type and mutant forms of SUP35 in yeast.
The centromeric URA3  plasmid pRS316-SUP35 was
kindly provided by Dr. M.D. Ter-Avanesyan (Institute of
Experimental Cardiology, Moscow). The pRS316-
SUP35A, pRS316-SUP35D, and pRS316-SUP35E con-
structs with the mutant T341A (ACC to GCC change using
the sense 5'-AAAAAGGCGTTATGCCATATTGGATGCTCC
and antisense 5'-GGAGCATCCAATATGGCAT-
AACGCCTTTTT primers), T341D (ACC to GAC change)
and T341E (ACC to GAA change) alleles (same primers
except for the mutated codon), respectively, were
obtained by site-directed mutagenesis of the PKA consen-
sus site threonine 341, using the QuikChange site-
directed mutagenesis kit (Stratagene). The centromeric
HIS3 plasmids were constructed by insertion of the XbaI-
XhoI  fragments, containing the wild-type or mutant
SUP35 genes under the control of the SUP35 promoter
into the same sites of pRS313. The 2μ DNA-based TRP1
plasmids were obtained by insertion of the SacI-XhoI frag-
ments, carrying the SUP35  promoter and wild-type or
mutated SUP35 genes, into the SacI-SalI sites of pFL45L.
The centromeric LEU2 plasmid pFL36-SUP35cter express-
ing the C-terminal part of wild-type Sup35p (amino acids
254 to 685) under the SUP35 promoter, was kindly pro-
vided by Dr. O. Namy (Institut de Génétique et Microbiol-
ogie, Orsay). The StuI-NcoI  fragment from pFL36-
SUP35cter, carrying the T341, was replaced by the same
fragment obtained from pRS313-SUP35A or pRS313-
SUP35D, resulting in pFL36-SUP35Acter and pFL36-
SUP35Dcter, to express the C-terminal domain of the A or
D mutants, respectively. The EcoR1-BamH1  fragments
from the three pFL36 vectors were inserted into the EcoR1-
BamH1  cleaved pHS8 plasmid (2μ-based DNA, HIS3
marker) to overexpress the wild-type, A or D, C-terminal
part of eRF3.
To express the entire wild-type, A and D Sup35p HA pro-
teins in yeast, the corresponding open reading frames
(without the stop codon) were amplified using the direct
(5'-CACTAGAATTCATGTCGGATTCAAACCAAGGC) and
reverse (5'-CAAGAGGATCCTCGGCAATTTTAACAATTT-
TACC) primers containing respectively the EcoRI  and
BamH1  sites (underlined), and cloned into the EcoRI-
BamH1 sites of the pYX212 vector (URA3, 2μ-based plas-
mid – R&D Systems, Mineapolis USA) under the control
of the constitutive TPI promoter. Constructs for the
expression in yeast of the C-terminus SUP35 HA proteins
were generated by inserting the PCR-amplified 3'-frag-
ments of the SUP35HA gene from pYX212 with the direct
(5'-CACGCGCTATTGGCCAAGACCCAAGG) and reverse
(5'-GAACAGCTCTAGAGATATCATGCGTAGTCAG-
GCTC) primers containing respectively the MscI and XbaI
sites (underlined), and cloned into the pFL36-SUP35cter
vector digested by MscI-XbaI.
pET-SUP35 for the expression of His6-tagged Sup35p in E.
coli was produced by inserting a PCR fragment amplified
from pRS316-SUP35 with the direct (5'-AGATATACATAT-
GTCGGATTCAAACCAAGGC) and reverse (5'-
GCCGGATCCTTACTCGGCAATTTTAACAATTTTACC)
primers containing extensions with NdeI and BamH1 sites
(underlined), respectively, into the NdeI-BamH1 cleaved
pET-28a vector (Novagen). The resulting construct con-
tains the 685 codons of SUP35 fused in frame to the 6 His
codons at the N terminus. The pET-SUP35A and pET-
SUP35D plasmids for the expression of the entire A and D
eRF3 mutants in E. coli were obtained by replacing in pET-
SUP35 the MscI fragment containing the mutation posi-
tion by the same fragment obtained by digestion of
pRS316-SUP35A and pRS316-SUP35D, respectively. The
pET-SUP35cter plasmid (pYSC2) was kindly provided by
Dr. R.H. Buckingham (Institut de Biologie Physico-
Chimique, Paris). The pET-SUP35Acter and pET-
SUP35Dcter, expressing in E. coli the N-terminal His6-
tagged eRF3 A or D C-terminus, respectively, were con-
structed by replacing in pET-SUP35cter the NcoI-StuI frag-
ment by the corresponding fragments from pRS313-
SUP35A or pRS313-SUP35D.
The plasmid for expression of Sup45p in E. coli was cre-
ated on the basis pET30a and kindly provided by V.N.
Urakov (Institute of Experimental Cardiology, Moscow).
The 2μ-based pGAD-C3 (LEU2 marker) and pGBDU-C3
(URA3 marker) vectors [39] were used to generate plas-
mids for the two-hybrid analysis. The pET-SUP35 vector
was digested by NdeI, then Klenow-filled, and digested by
BamH1. The resulting fragment carrying the entire SUP35
open reading frame was cloned into the SmaI-BamH1 sites
of the pGAD-C3 and pGBDU-C3 plasmids. The Gal4 acti-
vating and binding domain fusions with the A and DBMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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Sup35 mutants were obtained by replacing the wild-type
NcoI-StuI fragments by the mutated fragments digested
from pRS313-SUP35A and pRS313-SUP35D. For SUP45,
a PCR fragment amplified from FS1 genomic DNA with
the direct (5'-CCATCGATGGATAACGAGGTT-
GAAAAAAATATTG) and reverse (5'-TTTTCTGCAGT-
TAAATGAAATCATAGTCGGATCC) primers containing
extensions with ClaI and PstI sites (underlined), respec-
tively, was cloned in frame into the ClaI-PstI  cleaved
pGAD-C3 and pGBDU-C3 vectors. The resulting plasmids
overexpress Sup45p fused to either the Gal4 activating or
Gal4 binding domains.
Purification of eRF3 and eRF1 proteins
Sup35 and Sup35cter proteins were purified as follows.
Expression was performed at 37°C using the transformed
E. coli Rosetta strains (Novagen) and LB medium supple-
mented with 17 μg/ml chloramphenicol and 50 μg/ml
kanamycin. When the cell culture reached an OD600 nm of
0.5, protein expression was induced with 0.5 mM IPTG
(Sigma) and the cells were grown for a further 3 h. The
cells were harvested by centrifugation and stored at -20°C.
The cell pellet was resuspended in 40 ml of 20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol,
and protease inhibitors. Cell lysis was completed by soni-
cation. The His-tagged protein was purified on an Ni-NTA
column (Qiagen Inc.), eluted with imidazole, and loaded
onto a SuperdexTM200 column (Amersham Pharmacia
Biotech) equilibrated with 20 mM Tris-HCl pH 7.5, 150
mM NaCl, and 10 mM β-mercaptoethanol. The homoge-
neity of the proteins was checked by SDS-PAGE.
The Sup45p with 6 His-residues on the N terminus was
expressed in E. coli and purified on Ni-NTA resin (Qia-
gen).
In vitro phosphorylation
Aliquots (2 μg) of purified N-terminally His6-tagged
Sup35 and Sup35cter proteins were added to a PKA reac-
tion buffer containing 25 mM Tris pH 7.5, 10 mM MgCl2,
and 2 μCi of [γ-32P]ATP (3000 Ci/mmol), and incubated
with 2.5 U of the PKA catalytic subunit (Sigma) at 30°C
for 30 min in a total volume of 40 μl. To test for the spe-
cificity of the reaction for PKA, 30 μg of PKA inhibitor
(PKI) (Sigma) were added to the reaction buffer to specif-
ically inhibit the activity of PKA. For mass spectrometry
analyses, Sup35p (100 μg) was phosphorylated by 75 U of
PKA with 750 μM unlabelled ATP in 1.2 ml. Phosphor-
ylated proteins were then TCA precipitated and loaded
onto 10% SDS-polyacrylamide gels, which were then
autoradiographed. For mass spectrometry analyses, the
gels were stained with Coomassie Blue, and the bands of
interest were excised for further analysis.
To investigate differences in electrophoretic mobility
between the in vitro phosphorylated and non-phosphor-
ylated protein forms, samples were loaded onto various
SDS-polyacrylamide gels and revealed by Coomassie
staining: 4–12% gradient polyacrylamide gel, or 10% acr-
ylamide/0.1% bis-acrylamide gel, or 10% ProSieve 50 gel,
which is a modified acrylamide formulation developed
for high performance protein gel electrophoresis (TEBU).
Mass spectrometry analysis
In-situ proteolysis
Protein bands were excised, sliced into 1 mm cubes, thor-
oughly washed with water and dehydrated in acetonitrile
for 10 min at 37°C. They were destained by several incu-
bations in 100 mM ammonium bicarbonate pH 8.5 con-
taining 50% acetonitrile, dehydrated again in acetonitrile
and vacuum dried. After reduction (10 mM DTT for 35
min at 56°C) and alkylation (55 mM iodoacetamide for
30 min at room temperature), each cube was reswollen in
20 μl 50 mM ammonium bicarbonate pH 8.5 containing
10% acetonitrile and 500 ng of trypsin (unmodified,
sequencing grade, Roche Diagnostics), and left on ice for
45 min before proteolysis (overnight at 37 °C). Superna-
tants were removed and peptides extracted sequentially
with 1% trifluoroacetic acid (TFA) and followed 1% TFA
in 60% acetonitrile. The resulting supernatants were com-
bined and dried.
Peptide purification
Tryptic peptides resuspended in 0.1% TFA were loaded
onto a 250 × 2,1 mm Vydac C18 reversed phase column
(300 Å pore size) and eluted with a 90 min linear gradient
of 0–70% acetonitrile in 0.1% TFA. The flow rate was 0.3
ml/min. Fractions were collected manually based on the
absorbance profile at 215 nm.
MALDI-TOF mass spectrometry analysis
An aliquot of unfractionated tryptic digest was resus-
pended in 10 μl 50% acetonitrile and 0.3% TFA, and 1 μl
was mixed in a 1:1 ratio with a saturated solution of a-
cyano-4-hydroxycinnamic acid in 0.3% TFA/50% ace-
tonitrile. An aliquot of each HPLC fraction was concen-
trated 20-fold under vacuum before 1 μl of the
concentrate was mixed with 1 μl of the matrix saturated
solution. The different mixes were deposited on a stand-
ard stainless probe and allowed to air dry. MALDI analysis
was performed on a Voyager-DE STR equipped with a 337
nm laser source (Applied Biosystems, USA). Spectra were
recorded in positive-ion reflectron mode, with a 20 kV
acceleration voltage in the ion source. External calibration
was performed with a mixture of 6 reference peptides cov-
ering the m/z 900–3700 Da range, allowing a mass accu-
racy of 10 to 30 ppm.BMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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Phosphopeptide and phosphorylation site identification
To ensure a reliable identification of phosphorylated pep-
tide(s), dephosphorylation experiments were performed
for unfractionated tryptic digests and HPLC fractions on
the MALDI target using alkaline phosphatase (1 unit/μl;
Roche) prior to analysis as described [45]. To characterize
the phosphorylation site in peptide [339–349], a Post-
source-decay MALDI-TOF (PSD) experiment was per-
formed. As tryptic peptides are difficult to fragment in
PSD-MALDI-TOF due to their proton sequestring C termi-
nus, the Chemically Assisted Fragmentation (CAF) tech-
nology was used. Based on the introduction of a
negatively charged sulphonic acid group to the N termi-
nus of peptides after lysine residue protection by their
conversion to homoarginine, this technology significantly
improves the sensitivity of PSD-MALDI by increasing the
fragmentation efficiency. Furthermore, the clarity of the
spectrum is improved as only the y-ion series is observed.
Indeed, only the y-ions (C-terminal fragments) retain a
net positive charge allowing them to be detected, while
the b-ions (N-terminal fragments) are neutral and cannot
be detected. Simplified mass data were obtained using the
Ettan CAF MALDI sequencing kit as described by the man-
ufacturer (GE Healthcare Amersham Biosciences).
Western blots
Protein samples were separated on SDS-polyacrylamide
gels and electrophoretically transferred to nitrocellulose
membranes [46]. Western blots were probed with either
affinity purified polyclonal rabbit antibodies against the
peptide 137–151 of Sup35p (a kind gift from Dr. S.
Lindquist), or a rabbit monoclonal antibody against
phospho-PKA substrates (detecting R-R-X-S*/T* motifs,
Cell Signaling). The bound antibodies were detected
using the Amersham ECL system.
In vivo labelling and immunoprecipitation
Yeast cells were grown in a low-phosphate YPD medium
(LP-YPD Broth, BIO 101 Systems) to the appropriate
OD600 (1.5 for the exponential phase, and 6 for the sta-
tionary phase). Cells in 1 ml growth medium, harvested
from 4 ml for the exponential and 1 ml for the stationary
phases were labeled by adding 250 μCi of [32P] ortho-
phosphate (Amersham) for 1 h at 30°C. The cells were
lysed by incubation for 10 min on ice with 100 μl of 1.85
M NaOH plus 1% β-mercaptoethanol. Proteins were then
precipitated by adding 100 μl of 50% TCA. The precipitate
was centrifuged at 15,000 g for 5 min, washed with 1 M
Tris base, resuspended in 50 μl of SDS-PAGE loading
buffer without β-mercaptoethanol [47], and dissociated
by heating for 10 min at 95°C. TNET buffer (0.6 ml; TNET
= 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, plus 1 mM phenylmethylsulphonyl flu-
oride (PMSF) and protease inhibitors) was added, and the
insoluble material was removed by centrifugation for 30
min at 12,000 g. The supernatant was incubated overnight
at 4°C with 50 μl rat monoclonal anti-HA antibody
(clone 3F10, Roche Diagnostics), plus 100 μl of 50% pro-
tein G-Agarose beads (Roche Diagnostics). Supernatants
were 10-fold concentrated using Vivaspin 500 ultrafiltra-
tion spin columns (10,000 MWCO PES, Sartorius AG),
and aliquots were loaded on 10% SDS-PAGE gels. Immu-
noprecipitates were washed twice with TNET buffer, twice
with 100 mM Tris-HCl pH 7.5, 300 mM NaCl, and once
with 25 mM Tris-HCl pH 7.5. The proteins were eluted by
incubation for 5 min at 95°C in 100 μl of 2-fold concen-
trated SDS-PAGE loading buffer. Samples were resolved
by 10% SDS-polyacrylamide gels and autoradiographed.
Quantification of readthrough efficiency
Yeast strains were transformed with pAC99 reporter fam-
ily plasmids. In each case, at least five independent trans-
formants, cultivated in the same conditions, were assayed.
Cells were broken using acid-washed glass beads, as
described [26]. Luciferase and β-galactosidase activities
were assayed in the same crude extract. Readthrough effi-
ciency is estimated by the ratio of luciferase activity to β-
galactosidase activity. To establish the relative activities of
β-galactosidase and luciferase when expressed in equimo-
lar amounts, the ratio of luciferase activity to β-galactosi-
dase from an in-frame control plasmid was taken as a
reference. Readthrough frequency, expressed as percent-
age, was calculated by dividing the luciferase/β-galactosi-
dase ratio obtained from each test construct by the same
ratio obtained with the in-frame control construct [24].
This allowed us to determine the percent readthrough
while controlling differences in mRNA abundance or effi-
ciency of translation initiation.
Two-hybrid analysis
The GAL4-based two-hybrid system [39] was used. pGAD
plasmids (empty pGAD, pGAD-SUP35, pGAD-SUP35A,
pGAD-SUP35D and pGAD-SUP45) were transformed
into the MATα pJ69-4A strain, and pGBDU plasmids
(empty pGBDU, pGBDU-SUP35, pGBDU-SUP35A,
pGBDU-SUP35D and pGBDU-SUP45) into the MATa
pJ69-4A strain. These transformants were mated in differ-
ent pairwise combinations overnight at 30°C on YPD
plates, and diploids selected on uracil and leucine omis-
sion medium. The two-hybrid interactions were assessed
by the ability to transactivate HIS3 or ADE2 reporter genes
(to confer growth either in the absence of adenine, or in
the absence of histidine and in presence of different con-
centrations of 3-amino-1,2,4-triazole (Sigma)). Interac-
tions were visualized on histidine, uracil and leucine
omission medium containing either 5 mM, 10 mM, or 25
mM 3-amino-1,2,4-triazole, and also on the more selec-
tive adenine, uracil and leucine omission medium. Simi-
lar interactions were detected on each medium when
Sup35 was fused to the Gal4 activating domain (pGADBMC Molecular Biology 2008, 9:22 http://www.biomedcentral.com/1471-2199/9/22
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vectors) and Sup45 to the binding domain (pGBDU vec-
tors). Lighter interactions were seen in the opposite com-
binations (Sup35 into pGBDU vectors and Sup45 into
pGAD vectors) on the histidine omission medium, and
no interaction at all on the adenine omission medium. As
negative control, diploids bearing the empty vector and
fusion constructs were used, and the HIS3  or  ADE2
reporter genes were not activated. Quantitative β-galactos-
idase assays were undertaken on lysates prepared from
each diploid strain in order to estimate the interaction
strength, but no coherent results were obtained because of
the leakiness of the promoter controlling the expression
of the lacZ gene (same level of β-galactosidase activity in
the diploid carrying at least one empty vector).
Assay for GTPase activity
The incubation mixture (12.5 μl) contained 2 μM [γ-32P]
GTP (sp. activity 4000–5000 cpm/pmole), 20 mM Tris-
HCl, pH 7.5, 30 mM NH4Cl, 15 mM MgCl2, 0.2 μM 80S
rabbit ribosomes, 0.32 μM Sup45p and 0.4 μM
Sup35pCter. The reaction was performed at 25°C for 30
min, stopped by adding 750 μl of 5% charcoal in 50 mM
NaH2PO4 on ice. The mixture was vortexed and centri-
fuged at 10,000 rpm for 10 min at 4°C. The [32P]Pi
released into 500 μl of supernatant was quantitated by liq-
uid scintillation counting. [32P]Pi release in the absence of
one out of the three protein components of the incuba-
tion mixture was measured and the average value
(8–10%) was subtracted for all samples.
The RF stimulating activity of Sup35pcter towards Sup45p 
in an in vitro termination assay
The RF stimulating activity of Sup35pcter towards Sup45p
was measured as described [8]. Stop-codon-dependent
hydrolysis of f[35S]Met-tRNAfMet associated with the AUG-
80S rabbit ribosome complex took place at 5 μM stop
codon (UAAA) that corresponded to ~10% of the satura-
tion level needed for complete fMet release with Sup45p
but without Sup35pcter. The RF activity was calculated as
the amount of f[35S]Met released in the presence of stop
codon; the value of f[35S]Met released in the absence of
stop codon was subtracted from all values.
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